Department of Cardiology, Odense University Hospital, Odense, Denmark.
Eur J Prev Cardiol. 2012 Dec;19(6):1496-502. doi: 10.1177/1741826711428063. Epub 2011 Oct 21.
The aim was to examine and compare the impact of HeartScore and coronary artery calcification (CAC) score on subsequent changes in the use of medication.
A total of 1156 healthy men and women, aged 50 or 60, had a baseline medical examination and a coronary artery CT-scan as a part of a screening programme. Using the European HeartScore, the total 10-year cardiovascular mortality risk was estimated (≥5% risk was considered as high). Risk factors and CAC scores were reported to both the patients and their general practitioner. Six months after the screening, follow-up questionnaires addressing current medication were mailed to the participants.
A completed questionnaire was returned by 1075 (93%) subjects. At follow up, the overall use of prophylactic medication was significantly increased. Of those with CAC (n = 462) or high HeartScore (n = 233), 21 and 19%, respectively, received lipid-lowering treatment, while 25 and 32%, respectively, received antihypertensive treatment. In multivariate logistic regression analyses, the presence of CAC was associated with an increased use of lipid-lowering treatment (OR 2.2; 95% CI 1.2-4.0), while the presence of a high HeartScore was associated with an increased use of lipid-lowering (OR 2.9; 95% CI 1.6-5.5) and antihypertensive medication (OR 3.4; 95% CI 1.9-6.0).
Knowledge of present cardiovascular risk factors like high HeartScore and/or CAC leads to beneficial changes in medication. However, at follow up only a minority of high-risk subjects did received prophylactic treatment. CAC score was not superior to HeartScore regarding these motivational outcomes.
旨在探讨和比较 HeartScore 和冠状动脉钙化(CAC)评分对随后药物使用变化的影响。
共有 1156 名年龄为 50 或 60 岁的健康男性和女性参加了一项筛查计划,接受了基线体检和冠状动脉 CT 扫描。使用欧洲 HeartScore 评估了总 10 年心血管死亡率风险(≥5%的风险被认为是高风险)。危险因素和 CAC 评分均报告给患者及其全科医生。在筛查后 6 个月,向参与者邮寄了一份关于当前用药情况的随访问卷。
1075 名(93%)参与者完成了问卷调查。随访时,预防性药物的总体使用量显著增加。在 CAC(n=462)或高 HeartScore(n=233)患者中,分别有 21%和 19%接受了降脂治疗,而分别有 25%和 32%接受了降压治疗。多变量逻辑回归分析显示,CAC 的存在与降脂治疗的使用增加相关(OR 2.2;95% CI 1.2-4.0),而高 HeartScore 的存在与降脂治疗(OR 2.9;95% CI 1.6-5.5)和降压药物(OR 3.4;95% CI 1.9-6.0)的使用增加相关。
了解高 HeartScore 和/或 CAC 等当前心血管危险因素会导致药物治疗的有益变化。然而,在随访时,只有少数高危患者接受了预防性治疗。在这些激励结果方面,CAC 评分并不优于 HeartScore。